
ACE Inhibitors Show Lower Risk of MACE for Older Patients With Type 2 Diabetes
For older patients with type 2 diabetes (T2D), initiating treatment with angiotensin-converting enzyme inhibitors (ACEIs) was associated with a trend toward lower risk of major adverse cardiac events (MACE) compared with angiotensin II receptor blockers ( …